- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02163746
Study to Compare Two Treatments for Axillary Hidradenitis Suppurativa: Carbon Dioxide Laser Versus Surgical Deroofing
February 15, 2022 updated by: Iltefat Hamzavi, Henry Ford Health System
A Prospective, Randomized, Controlled Clinical Trial Comparing the Efficacy Carbon Dioxide (CO2) Laser Excision Versus Surgical Deroofing in the Treatment of Hidradenitis Suppurativa
This study compares two well-known treatment options for Stage 2 hidradenitis suppurativa: carbon dioxide (CO2) laser excision versus surgical deroofing.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- We will be treating patients with Stage 2 (interconnected sinus tracts and nodules) hidradenitis suppurativa who have somewhat active involvement (including drainage) in the axillae. We will only be treating ONE axilla per patient.
- After patients are screened and deemed appropriate candidates, they will be randomized to a treatment group: CO2 laser excision or surgical deroofing.
- For each patient, there will be a single intervention (either CO2 laser excision or surgical deroofing), after which there will be 5 planned follow-up appointment at following intervals: 1 week, 2 weeks, 4 weeks, 3 months, 6 months. This will take place over course of 6 months for each patient.
- During the study, subjects will be asked to provide information on quality of life measures, and filling out questionnaires (DLQI and Skindex29) at each visit.
Inclusion criteria:
- Be at least 13 years old and have a diagnosis of hidradenitis affecting the underarms.
- Agree to follow and undergo all study-related procedures, and follow-up over six month period.
Exclusion criteria:
- Patients who have already undergone surgical excision to affected area.
- Patients who are pregnant or breast feeding will not be able to take part in the study due to the unknown effects of CO2 laser in pregnant females, as well as risk of lidocaine use during pregnancy and breastfeeding
- Patients with a history of allergy to lidocaine or topical anesthetics will not be able to take part in this study.
- Patients with a history of vitiligo as the CO2 laser may cause new spots of depigmentation.
- Patients with a pacemaker/defibrillator in place.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
13 years to 100 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be at least 13 years old
- Be otherwise healthy
- Have a diagnosis of HS
- Patients must have Hurley Stage II HS affecting the axilla, with one or more widely separated recurrent abscesses, with formation of a sinus tract and/or scarring
- Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form
- Agree to follow and undergo all study-related procedures
- If applicable, minors must have permission of legal guardian for participation in the study
Exclusion criteria:
- Patients with HS Hurley stage I and III will be excluded from participation
- Patients who are pregnant or breast feeding will not be able to take part in the study due to the unknown effects of CO2 laser in pregnant females, as well as risk of lidocaine use during pregnancy and breastfeeding
- Any reason the investigator feels the patient should not participate in the study
- If a patient misses ≥ 2 consecutive study visits, the patient will be excluded from further participation in this trial
- History of allergy to lidocaine or topical anesthetics
- Patients with a history of vitiligo as the CO2 laser may cause new spots of depigmentation
- Patients with a pacemaker/defibrillator in place
- Patients who have previously undergone surgical intervention and recurred in the axilla to be treated
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CO2 (carbon dioxide) laser
Patients randomized to this group will undergo CO2 laser excision of the sinus tracts in affected axilla
|
|
Active Comparator: Surgical Deroofing
Patients randomized to this group will undergo surgical deroofing of the sinus tracts in affected axilla
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life Measures
Time Frame: June 2014-February 2014
|
Quality of Life measures will be measured via DLQI and Skindex29 patient surveys.
|
June 2014-February 2014
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 14, 2015
Primary Completion (Actual)
December 20, 2015
Study Completion (Actual)
June 7, 2016
Study Registration Dates
First Submitted
June 12, 2014
First Submitted That Met QC Criteria
June 13, 2014
First Posted (Estimate)
June 16, 2014
Study Record Updates
Last Update Posted (Actual)
March 2, 2022
Last Update Submitted That Met QC Criteria
February 15, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8606
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hidradenitis Suppurativa
-
Yale UniversityNot yet recruitingHidradenitis Suppurativa | Hidradenitis Suppurativa, Acne Inversa | Hidradenitis Suppurativa \(HS\)United States
-
Boehringer IngelheimNot yet recruiting
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Canada, Bulgaria, Italy, Spain, Germany, Poland, France, Australia, Denmark, United Kingdom
-
Novartis PharmaceuticalsAvailableHidradenitis Suppurativa (HS)
-
AbbVie (prior sponsor, Abbott)CompletedHidradenitis Suppurativa (HS)
-
InflaRx GmbHQuintiles, Inc.CompletedHidradenitis Suppurativa (HS)United States, Bulgaria, Canada, Denmark, France, Germany, Greece, Netherlands, Poland
-
Erasmus Medical CenterNot yet recruitingHidradenitis Suppurativa, Acne Inversa
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Austria, Canada, Czechia, Spain, Germany, Poland, Netherlands, Belgium, France, Greece, Japan
-
Wake Forest University Health SciencesActive, not recruiting
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Austria, Belgium, Canada, Germany, Poland, Spain, Australia, Denmark, France, United Kingdom, Japan, Bulgaria, Netherlands, Czechia, Greece, Italy
Clinical Trials on CO2 (carbon dioxide) laser
-
Sun Yat-sen UniversityRecruitingKeratosis | Eyelid Tumor | Pigmented Nevi | Xanthelasma PalpebrarumChina
-
Hospital Clinic of BarcelonaCompleted
-
Massachusetts General HospitalRecruitingBurn Scar | Hypertrophic ScarUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions
-
Capnia, Inc.CompletedTrigeminal NeuralgiaUnited States
-
Assiut UniversityUnknown
-
Bispebjerg HospitalGalderma R&DCompletedActinic Keratosis | Sun Damaged Skin | Solar Keratosis | Solar Skin Damage
-
Daping Hospital and the Research Institute of Surgery...Completed
-
Jose R. Reyes Memorial Medical CenterCompletedStriae GravidarumPhilippines
-
Qilu Hospital of Shandong UniversityRecruitingStress Urinary IncontinenceChina